Pfizer Inc.

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and globally. It operates through three segments: Biopharma, PC1, and Pfizer Ignite. The company's portfolio includes internal medicine products like Eliquis for cardiovascular metabolic diseases, migraine treatments such as Nurtec ODT/Vydura and Zavzpret, and vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands. It also offers Paxlovid for COVID-19, inflammation and immunology products like Xeljanz and Enbrel, rare disease treatments including Vyndaqel family and Genotropin, anti-infective and immunoglobulin medicines like Zavicefta and Octagam, and a broad oncology portfolio featuring Ibrance, Xtandi, Padcev, Adcetris, and biosimilars such as Inflectra, Retacrit, and Ruxience.

Pfizer Inc. is listed on the New York Stock Exchange (NYSE) under the ticker symbol PFE. Its shares are traded in US Dollars (USD), reflecting its primary listing in the United States. As a US-based company, its financial reporting and stock trading are conducted in USD, making it accessible to investors on major US exchanges.

Pfizer Inc. operates in the Healthcare sector, specifically within the Drug Manufacturers - General industry. This classification indicates that Pfizer is a broad-based pharmaceutical company involved in the research, development, manufacturing, and marketing of a wide range of biopharmaceutical products. As a drug manufacturer, it focuses on creating therapies for various therapeutic areas, including internal medicine, vaccines, inflammation, immunology, rare diseases, and oncology.

Pfizer's portfolio spans multiple therapeutic areas. In cardiovascular metabolic diseases, it offers Eliquis. For migraine, it has Nurtec ODT/Vydura and Zavzpret. Its vaccine portfolio includes Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba. Paxlovid is used for COVID-19 treatment. Inflammation and immunology products include Xeljanz, Enbrel, Cibinqo, Litfulo, Eucrisa, and Velsipity. Rare disease treatments cover amyloidosis, hemophilia, and endocrine diseases under brands like Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, and Hympavzi. Anti-infective and immunoglobulin medicines include Zavicefta, Octagam, and Panzyga. Oncology offerings include Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak, Talzenna, and biosimilars like Inflectra, Retacrit, Ruxience, Zirabev, Trazimera, and Nivestym.

Pfizer generates revenue through the discovery, development, manufacturing, marketing, distribution, and sale of biopharmaceutical products globally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The Biopharma segment likely encompasses its core innovative medicines and vaccines. PC1 may refer to its contract manufacturing or primary care business. Pfizer Ignite is a segment focused on providing services to biotech companies. Revenue comes from a diverse portfolio of branded drugs, vaccines, and biosimilars across therapeutic areas such as cardiovascular, migraine, vaccines, COVID-19, inflammation, immunology, rare diseases, anti-infectives, and oncology. The company's global presence in the United States and other countries allows it to capture revenue from multiple markets.